|
DFMO Clinical Trials
5 actively recruiting trials across 5 locations
Also known as: Difluoromethylornithine, Eflornithine, α-difluoromethylornithine, difluoromethylornithine, eflornithine, iWilfin
Pipeline
Phase 2: 3Phase 1/2: 2
Top Sponsors
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
- Montefiore Medical Center1
- Giselle Sholler1
- Emily K. Sims1
- Aminex Therapeutics, Inc.1
Indications
- Cancer4
- Type 1 Diabetes1
- Ewing's Tumor Recurrent1
- Osteosarcoma Recurrent1
- HER2-low Hormone Receptor Positive Breast Cancer1
Birmingham, Alabama1 trial
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
University of Alabama/Children's of Alabama
Phase 2
Los Angeles, California1 trial
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
START Los Angeles
Phase 1/2
Aurora, Colorado1 trial
TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
Barbara Davis Center
Phase 2
Baltimore, Maryland1 trial
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
Phase 2
The Bronx, New York1 trial
DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
Montefiore Medical Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.